Stay updated with breaking news from Runway Expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01.05.2024 - - Achieved $14.1 Million in Net Revenue from Sales of COSELA (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib ...
First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data...
- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate Sacituzumab Govitecan Suggest a Potentially Meaningful Improvement in Overall Survival for Patients...